接受华法林治疗患者抗凝控制的决定因素。
Determinants of anticoagulant control in patients receiving warfarin.
作者信息
O'Malley K, Stevenson I H, Ward C A, Wood A J, Crooks J
出版信息
Br J Clin Pharmacol. 1977 Jun;4(3):309-14. doi: 10.1111/j.1365-2125.1977.tb00718.x.
Abstract
1 A hospital-based drug information system has been used to assess the time for which patients treated with warfarin were outside the range of Thrombotest values 5-10% and 5-15% and to examine possible contributory factors in situations where anticoagulation fell outside these ranges. 2 Anticoagulant control varied with the age of the patient and with concomitant drug therapy but not with patient sex or indication of anticoagulation. 3 Most patients were 'under-anticoagulated' at some stage but patients over 70 years spent significantly longer in the 5-10% range than those in the age range 30-59 years and Thrombotest values of less than 5% were found predominantly in the older group. 4 Patients given drugs known to interact with warfarin spent least time in the defined Thrombotest ranges. Those on drugs known to potentiate warfarin effect had significantly lower Thrombotest values than the other patients studied.
摘要
- 一个基于医院的药物信息系统已被用于评估接受华法林治疗的患者超出凝血酶检测值5 - 10%和5 - 15%范围的时间，并检查抗凝作用超出这些范围时可能的促成因素。2. 抗凝控制随患者年龄和伴随药物治疗而变化，但不随患者性别或抗凝指征而变化。3. 大多数患者在某些阶段处于“抗凝不足”状态，但70岁以上的患者在5 - 10%范围内花费的时间明显长于30 - 59岁年龄组的患者，且凝血酶检测值低于5%的情况主要出现在老年组。4. 服用已知与华法林相互作用药物的患者在规定的凝血酶检测范围内花费的时间最少。服用已知增强华法林作用药物的患者的凝血酶检测值明显低于其他研究患者。
相似文献
1
Determinants of anticoagulant control in patients receiving warfarin.接受华法林治疗患者抗凝控制的决定因素。
Br J Clin Pharmacol. 1977 Jun;4(3):309-14. doi: 10.1111/j.1365-2125.1977.tb00718.x.
2
Aging and the anticoagulant response to warfarin therapy.衰老与对华法林治疗的抗凝反应
Ann Intern Med. 1992 Jun 1;116(11):901-4. doi: 10.7326/0003-4819-116-11-901.
3
No effect of terodiline on anticoagulation effect of warfarin and steady-state plasma levels of warfarin enantiomers in healthy volunteers.特罗地林对健康志愿者华法林抗凝作用及华法林对映体稳态血浆水平无影响。
Ther Drug Monit. 1989 Nov;11(6):667-73. doi: 10.1097/00007691-198911000-00010.
4
Predicting patients' warfarin requirements.
Lancet. 1977 Oct 22;2(8043):854-5. doi: 10.1016/s0140-6736(77)90786-3.
5
Effect of influenza vaccine on warfarin anticoagulation.
Clin Pharmacol Ther. 1984 Mar;35(3):416-8. doi: 10.1038/clpt.1984.52.
6
Long-term oral anticoagulant therapy in elderly patients.老年患者的长期口服抗凝治疗
Age Ageing. 1988 Nov;17(6):388-96. doi: 10.1093/ageing/17.6.388.
7
Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices.饮食中维生素K的变异性会影响国际标准化比值（INR）凝血指标。
Int J Vitam Nutr Res. 2006 Mar;76(2):65-74. doi: 10.1024/0300-9831.76.2.65.
8
Temafloxacin does not potentiate the anticoagulant effect of warfarin in healthy subjects.替马沙星不会增强健康受试者中华法林的抗凝作用。
Clin Pharmacokinet. 1992;22 Suppl 1:102-6. doi: 10.2165/00003088-199200221-00017.
9
Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.在一项三阶段、开放标签、多剂量、单周期研究中，研究了依沙佐匹坦醋酸酯对健康受试者华法林稳态药代动力学和药效学的影响。
Clin Ther. 2010 Jan;32(1):179-92. doi: 10.1016/j.clinthera.2010.01.014.
10
The potentiation of warfarin anticoagulation by amiodarone.胺碘酮对华法林抗凝作用的增强作用。
Circulation. 1982 May;65(5):1025-9. doi: 10.1161/01.cir.65.5.1025.
引用本文的文献
1
Usefulness of STOPP/START criteria and Beers criteria for prescribing in geriatric patients in a tertiary health care center, Raipur, Central India.印度中部赖布尔一家三级医疗中心采用STOPP/START标准和Beers标准指导老年患者用药的效用
J Family Med Prim Care. 2022 Nov;11(11):7064-7071. doi: 10.4103/jfmpc.jfmpc_733_22. Epub 2022 Dec 16.
2
High intra- and inter-individual variability of plasma vitamin K concentrations in patients with atrial fibrillation under warfarin therapy.华法林治疗的房颤患者血浆维生素K浓度存在较高的个体内和个体间变异性。
Eur J Clin Nutr. 2015 Jun;69(6):703-6. doi: 10.1038/ejcn.2015.41. Epub 2015 Apr 1.
3
Epidemiology of adverse drug reactions in the elderly by drug class.按药物类别划分的老年人药物不良反应流行病学。
Drugs Aging. 1999 Mar;14(3):231-9. doi: 10.2165/00002512-199914030-00005.
4
Factors affecting the maintenance dose of warfarin.影响华法林维持剂量的因素。
J Clin Pathol. 1993 Apr;46(4):382-3. doi: 10.1136/jcp.46.4.382-c.
5
Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin.消旋华法林多次给药期间患者体内华法林对映体及代谢产物的处置情况。
Br J Clin Pharmacol. 1994 Jun;37(6):563-9. doi: 10.1111/j.1365-2125.1994.tb04305.x.
6
Effect of age upon the induction and maintenance of anticoagulation with warfarin.
Postgrad Med J. 1995 Mar;71(833):153-5. doi: 10.1136/pgmj.71.833.153.
7
Anticoagulants in older patients. A safety perspective.老年患者的抗凝剂。安全性视角。
Drugs Aging. 1995 Jan;6(1):45-54. doi: 10.2165/00002512-199506010-00004.
8
Drug epidemiology and clinical pharmacology: their contribution to patient care.药物流行病学与临床药理学：它们对患者护理的贡献。
Br J Clin Pharmacol. 1983 Oct;16(4):351-7. doi: 10.1111/j.1365-2125.1983.tb02177.x.
9
Effect of age and sex on acenocoumarol requirements.
Br J Clin Pharmacol. 1984 Oct;18(4):475-9. doi: 10.1111/j.1365-2125.1984.tb02494.x.
10
The potentiation of acenocoumarol anticoagulant effect by amiodarone.胺碘酮对醋硝香豆素抗凝作用的增强作用。
Br J Clin Pharmacol. 1984 Sep;18(3):355-60. doi: 10.1111/j.1365-2125.1984.tb02476.x.
本文引用的文献
1
Effect of age and sex on human drug metabolism.年龄和性别对人体药物代谢的影响。
Br Med J. 1971 Sep 11;3(5775):607-9. doi: 10.1136/bmj.3.5775.607.
2
Adult lean body mass declines with age: some longitudinal observations.成人瘦体重随年龄增长而下降：一些纵向观察结果。
Metabolism. 1970 Sep;19(9):653-63. doi: 10.1016/0026-0495(70)90062-4.
3
Vitamin K deficiency in the elderly.老年人维生素K缺乏症
Gerontol Clin (Basel). 1970;12(1):10-7. doi: 10.1159/000245257.
4
Drug interactions with coumarin anticoagulants. 2.香豆素类抗凝剂的药物相互作用。2.
N Engl J Med. 1971 Sep 2;285(10):547-58. doi: 10.1056/NEJM197109022851005.
5
Long-term anticoagulant therapy after myocardial infarction in women.女性心肌梗死后的长期抗凝治疗。
Br Med J. 1968 Sep 7;3(5618):571-4. doi: 10.1136/bmj.3.5618.571.
6
Age as a determinant of sensitivity to warfarin.年龄作为华法林敏感性的一个决定因素。
Br J Clin Pharmacol. 1977 Jun;4(3):315-20. doi: 10.1111/j.1365-2125.1977.tb00719.x.
Zotero 插件